Fate Therapeutics
FATE · Nasdaq · United States
Share price · FATE
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when FATE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-10.5%
Nothing announced by FATE that day or the session before.
- 16 Nov 2026-10.9%
Nothing announced by FATE that day or the session before.
- 12 Nov 2026-16.5%
- 11 Nov 2026-9.3%
- 10 Nov 2026-8.8%
- 20 Oct 2026+10.8%
Nothing announced by FATE that day or the session before.
- 3 Jun 2026-13.6%
Nothing announced by FATE that day or the session before.
- 5 May 2026+31.1%
Nothing announced by FATE that day or the session before.
- 4 May 2026+17.6%
Nothing announced by FATE that day or the session before.
- 1 May 2026+22.4%
Nothing announced by FATE that day or the session before.
Share of unusual movement by asset
For each asset, the share of FATE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $24M | $44M+ $95M short-term inv. | $31M-$28M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $2.1M | $24M | $32M+ $121M short-term inv. | $30M-$23M operating cash flow | report ↗ |
| 2026-Q1 | $1.3M | $25M | $40M+ $135M short-term inv. | $31M-$31M operating cash flow | report ↗ |
| 2025-Q3 | $1.7M | $26M | $41M+ $175M short-term inv. | $32M-$24M operating cash flow | report ↗ |
| 2025-Q2 | $1.9M | $27M | $41M+ $182M short-term inv. | $34M-$25M operating cash flow | report ↗ |
| 2025-Q1 | $1.6M | $29M | $45M+ $196M short-term inv. | $38M-$34M operating cash flow | report ↗ |
| 2024-Q3 | $3.1M | $35M | $38M+ $259M short-term inv. | $48M-$29M operating cash flow | report ↗ |
| 2024-Q2 | $6.8M | $35M | $37M+ $268M short-term inv. | $38M-$32M operating cash flow | report ↗ |
| 2024-Q1 | $1.9M | $32M | $121M | $48M-$33M operating cash flow | report ↗ |
| 2023-Q3 | $1.9M | $34M | $33M | $45M-$38M operating cash flow | report ↗ |
| 2023-Q2 | $0.9M | $41M | $47M | $53M-$28M operating cash flow | report ↗ |
| 2023-Q1 | $59M | $66M | $42M | $19M-$29M operating cash flow | report ↗ |
| 2022-Q3 | $15M | $80M | $82M | $84M-$55M operating cash flow | report ↗ |
| 2022-Q2 | $19M | $81M | $55M | $76M-$53M operating cash flow | report ↗ |
| 2022-Q1 | $18M | $72M | $65M | $66M-$65M operating cash flow | report ↗ |
| 2021-Q3 | $14M | $53M | $129M | $43M-$33M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $6.7M | $108M | $47M+ $157M short-term inv. | $34M-$106M operating cash flow | report ↗ |
For the full year 2025, Fate Therapeutics reported revenue of $6.65M, down 51.2% YoY from $13.63M, and R&D spend of $107.83M, down 20.1% YoY from $135M. Cash and equivalents were $46.63M, with a net loss of $136.31M and quarterly net burn of $136.32M.
Management projected operating runway through year-end 2027, supported by $205.1M in cash, cash equivalents, and investments and a 30% reduction in 2025 operating expenses versus 2024. Clinically, FT819 advanced as an outpatient, same-day-discharge off-the-shelf CAR T-cell therapy in an autoimmune basket study, with 15 systemic lupus erythematosus patients, four systemic sclerosis patients, and one idiopathic inflammatory myopathy patient treated, and the first systemic sclerosis patient showed meaningful disease improvement at the three-month evaluation. FT836, a MICA/B-targeted off-the-shelf CAR T-cell therapy, demonstrated early colorectal cancer activity, including a greater than 50% reduction in CEA levels and tumor reduction across all target lesions without conditioning chemotherapy. FT839 preclinical data were also presented, with IND-enabling activities ongoing.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $14M | $135M | $36M+ $243M short-term inv. | $47M-$123M operating cash flow | report ↗ |
| 2023-FY | $64M | $173M | $42M+ $273M short-term inv. | $40M-$132M operating cash flow | report ↗ |
| 2022-FY | $96M | $320M | $61M+ $375M short-term inv. | $70M-$248M operating cash flow | report ↗ |
| 2021-FY | $56M | $216M | $134M+ $482M short-term inv. | $53M-$163M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 7 sales ($336K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-03 | Adawi Kamal · Chief Financial Officer | Open-market sale | 6,582 | $2.05 | $14K | Form 4 |
| 2026-08-04 | Valamehr Bahram · director, President and CEO | Open-market sale | 43,947 | $2.46 | $108K | Form 4 |
| 2026-08-04 | TAHL CINDY · See Remarks | Open-market sale | 38,800 | $2.46 | $95K | Form 4 |
| 2026-06-12 | Hamill Laura · director | Award / grant (derivative) | 175,800 | — | — | Form 4 |
| 2026-06-12 | RASTETTER WILLIAM H · director | Award / grant (derivative) | 87,900 | — | — | Form 4 |
| 2026-06-12 | ABERNETHY MATT · director | Award / grant (derivative) | 87,900 | — | — | Form 4 |
| 2026-06-12 | Agarwal Shefali · director | Award / grant (derivative) | 87,900 | — | — | Form 4 |
| 2026-06-12 | EPSTEIN ROBERT S · director | Award / grant (derivative) | 87,900 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 155 reporting institutions held 74.1M shares ($83.2M, 63.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Redmile Group, LLC | 12,872,946 | $15.4M |
| 2 | BlackRock, Inc. | 10,068,614 | $12.1M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 4,192,063 | $5.0M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,134,585 | $5.0M |
| 5 | TWO SIGMA INVESTMENTS, LP | 3,466,786 | $4.2M |
| 6 | JOHNSON & JOHNSON | 3,379,064 | $4.1M |
| 7 | AQR CAPITAL MANAGEMENT LLC | 3,001,521 | $3.6M |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 2,974,683 | $3.6M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2,590,429 | $3.1M |
| 10 | STATE STREET CORP | 2,263,173 | $2.7M |
| 11 | UBS Group AG | 1,821,715 | $2.2M |
| 12 | GOLDMAN SACHS GROUP INC | 1,327,757 | $1.6M |
| 13 | TANG CAPITAL MANAGEMENT LLC | 1,167,773 | $1.4M |
| 14 | CITADEL ADVISORS LLC | 942,926 | $1.1M |
| 15 | DIMENSIONAL FUND ADVISORS LP | 883,790 | $1.1M |